<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04092101</url>
  </required_header>
  <id_info>
    <org_study_id>CHRMS19-0130</org_study_id>
    <secondary_id>U54DA036114-06</secondary_id>
    <nct_id>NCT04092101</nct_id>
  </id_info>
  <brief_title>Low Nicotine Content Cigarettes in Vulnerable Populations: Opioid Use Disorder</brief_title>
  <official_title>Low Nicotine Content Cigarettes in Vulnerable Populations: Opioid Use Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Vermont</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Food and Drug Administration (FDA)</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Vermont</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prevalence of smoking among individuals with opioid use disorder (OUD) is six-fold that of
      the general US adult population. The mortality rate of opioid-dependent smokers is four times
      that of opioid-dependent nonsmokers, and their response to smoking cessation interventions is
      notoriously poor. A national policy of reducing the nicotine content of cigarettes has the
      potential to be an effective method of reducing tobacco use prevalence, dependence, and
      related adverse health outcomes. Controlled trials in the general smoker population have
      demonstrated that switching smokers to low nicotine content cigarettes results in reductions
      in cigarettes per day (CPD), dependence and tobacco toxicant exposure, with few adverse
      consequences. The investigators believe that the impact of reduced nicotine standards on use
      of combusted cigarettes in this population will be moderated considerably by other tobacco
      market conditions including (1) availability of alternative sources of non-combusted
      nicotine, and (2) whether these alternatives are available under conditions that optimize
      their appeal. The investigators hypothesize the same for other vulnerable populations as
      well, but achieving significant reductions in use of combusted cigarettes in smokers with OUD
      seems especially unlikely in the absence of readily available and appealing alternative
      sources of non-combusted nicotine.

      The goal of the proposed trial is to experimentally model whether increased availability and
      appeal of an alternative, non-combusted source of nicotine (e-cigarettes) will enhance the
      effectiveness of a reduced nicotine standard for cigarettes in smokers with OUD.
      Additionally, the investigators will test whether allowing participants to personalize the
      favor of the e-liquid alters any moderating effects their availability may have on tobacco
      cigarette smoking.

      Daily smokers who are receiving methadone or buprenorphine treatment will be recruited at
      University of Vermont and Johns Hopkins University.

      The investigators will study two research cigarettes referred to here as RC1 and RC2. One of
      these cigarettes will be a normal nicotine content cigarette and the other will be a reduced
      nicotine content cigarette. Investigators will study two e-cigarette conditions referred to
      here as EC1 and EC2. Both e-cigarette conditions will involve the same commercially available
      devices and same nicotine-containing e-liquid, but in one condition that e-liquid will be
      available only in tobacco flavor while in the other condition that e-liquid will be available
      in multiple flavors from which participants can choose based on personal taste preference.
      Participants will be assigned to one of the following four study conditions: (1) RC1 only;
      (2) RC2 only; (3) RC2 + EC1; (4) RC2 + EC2.

      Participants will be asked to use only their assigned study products for 16 weeks. Outcome
      measures include total CPD, cigarette demand assessed by behavioral economics-based purchase
      tasks, craving, withdrawal, psychiatric symptoms, breath carbon monoxide (CO), biomarkers of
      tobacco toxicant exposure, brain function and structure, and airway inflammation (fractional
      nitric oxide concentration in exhaled breath [FeNO]).
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    COVID19 pandemic
  </why_stopped>
  <start_date type="Actual">September 24, 2019</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double blind dosing of tobacco cigarette nicotine levels.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Cigarettes Smoked Per Day</measure>
    <time_frame>16 weeks</time_frame>
    <description>Cigarettes per day will be assessed for use of cigarettes with different nicotine content.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">310</enrollment>
  <condition>Tobacco Use Disorder</condition>
  <arm_group>
    <arm_group_label>RC 1 only</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Research Cigarettes #1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RC 2 only</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Research Cigarettes #2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RC 2 + EC 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Research Cigarettes #2 plus E-cigarettes #1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RC 2 + EC 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Research Cigarettes #2 plus E-cigarettes #2</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cigarettes with varying nicotine content</intervention_name>
    <description>1) Altering the nicotine content of the tobacco research cigarette</description>
    <arm_group_label>RC 1 only</arm_group_label>
    <arm_group_label>RC 2 + EC 1</arm_group_label>
    <arm_group_label>RC 2 + EC 2</arm_group_label>
    <arm_group_label>RC 2 only</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>E-Cigarettes</intervention_name>
    <description>1) Altering the availability of e-cigarettes; 2) Altering option to personalize the e-liquid in the e-cig condition</description>
    <arm_group_label>RC 2 + EC 1</arm_group_label>
    <arm_group_label>RC 2 + EC 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Maintained on opioid medication

          -  21 to 70 years old

        Exclusion Criteria:

          -  Not maintained on opioid medication

          -  Under 21 years old

          -  Over 70 years old
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stacey C. Sigmon, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Vermont</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catie Markesich</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>September 13, 2019</study_first_submitted>
  <study_first_submitted_qc>September 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2019</study_first_posted>
  <last_update_submitted>June 8, 2020</last_update_submitted>
  <last_update_submitted_qc>June 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Vermont</investigator_affiliation>
    <investigator_full_name>Stacey C. Sigmon</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Biomarkers of Exposure</keyword>
  <keyword>Compensatory Smoking</keyword>
  <keyword>Nicotine Dependence</keyword>
  <keyword>Reduced Nicotine Cigarettes</keyword>
  <keyword>Affective Disorders</keyword>
  <keyword>Tobacco Withdrawal</keyword>
  <keyword>Vulnerable Populations</keyword>
  <keyword>E-Cigarettes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Tobacco Use Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

